We are live on ! Find out more
SLDB icon

Solid Biosciences

55 hedge funds and large institutions have $466M invested in Solid Biosciences in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 2

356% more capital invested

Capital invested by funds: $102M → $466M (+$364M)

267% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 6

56% more call options, than puts

Call options by funds: $248K | Put options by funds: $159K

41% more funds holding

Funds holding: 3955 (+16)

10.21% more ownership

Funds ownership: 82.45%92.66% (+10%)

Holders
55
Holders Change
+16
Holders Change %
+41.03%
% of All Funds
0.79%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
22
Increased
24
Reduced
2
Closed
6
Calls
$248K
Puts
$159K
Net Calls
+$89K
Net Calls Change
+$47K
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$92M +$31.9M +3,410,713 +98%
RCM
2
RA Capital Management
Massachusetts
$57.7M +$8.46M +904,160 +26%
BCLSI
3
Bain Capital Life Sciences Investors
Massachusetts
$53.7M +$8.46M +904,160 +29%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$33.8M +$23.8M +2,538,897 New
AG
5
Artal Group
Luxembourg
$33.3M +$14.9M +1,590,781 +175%
DM
6
Deerfield Management
New York
$30.1M +$21.2M +2,260,398 New
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$23.9M +$16.9M +1,808,440 New
SCM
8
Silverarc Capital Management
Massachusetts
$17.6M +$6.83M +730,210 +123%
Vanguard Group
9
Vanguard Group
Pennsylvania
$16.6M +$8.61M +920,404 +284%
VPC
10
Vestal Point Capital
New York
$13.8M +$9.37M +1,000,915 +2,937%
FC
11
Finepoint Capital
Massachusetts
$12.8M
LCM
12
Laurion Capital Management
New York
$12.4M
Millennium Management
13
Millennium Management
New York
$9.76M +$6.86M +733,081 New
MIM
14
Monashee Investment Management
Massachusetts
$8.26M +$5.8M +620,000 New
Walleye Capital
15
Walleye Capital
New York
$7.68M +$4.23M +451,707 +363%
Invesco
16
Invesco
Georgia
$6.29M +$4.42M +472,107 New
Alyeska Investment Group
17
Alyeska Investment Group
Illinois
$5.52M -$2.08M -222,664 -35%
BlackRock
18
BlackRock
New York
$4.09M +$1.81M +192,968 +169%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$3.17M +$1.35M +144,172 +154%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$2.9M +$1.72M +184,157 +554%
Goldman Sachs
21
Goldman Sachs
New York
$2.71M +$1.91M +203,748 New
ACM
22
ADAR1 Capital Management
Texas
$2.71M +$1.89M +202,204 +20,220%
Qube Research & Technologies (QRT)
23
Qube Research & Technologies (QRT)
United Kingdom
$1.74M +$1.22M +130,647 +13,064,700%
AI
24
Atom Investors
Texas
$1.35M +$950K +101,509 New
Two Sigma Investments
25
Two Sigma Investments
New York
$1.16M +$470K +50,190 +135%

SLDB Hedge Fund Activity: Q1 2024 in Review

55 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2024, worth a combined $466M — up 356% from $102M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new SLDB positions and 6 closed out — a net gain of 16 holders — while 24 added to existing stakes and 2 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $31.9M. The largest seller was Camber Capital Management, exiting entirely with an estimated $8.71M sold.

  • 55 institutional investors held Solid Biosciences (SLDB) as of Q1 2024, up from 39 in Q4 2023.
  • Funds reported $466M of Solid Biosciences stock for Q1 2024, up 356% quarter-over-quarter.
  • 22 funds opened new Solid Biosciences positions in Q1 2024 and 6 closed out, a net change of +16 holders.
  • The largest Solid Biosciences buyer in Q1 2024 was Perceptive Advisors, an estimated $31.9M added.
  • The largest Solid Biosciences seller in Q1 2024 was Camber Capital Management, an estimated $8.71M sold.

Based on aggregated 13F filings for Q1 2024.